Trial Profile
A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Poly ICLC (Primary) ; Poly ICLC (Primary) ; Tremelimumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cutaneous T-cell lymphoma; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Prostate cancer; Renal cancer; Sarcoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2022 Status changed from active, no longer recruiting to completed.
- 15 Nov 2021 Planned End Date changed from 1 Dec 2022 to 1 Feb 2022.
- 15 Nov 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Feb 2022.